Bier J, Benders P, Wenzel M, Bitter K
Cancer. 1979 Oct;44(4):1194-200. doi: 10.1002/1097-0142(197910)44:4<1194::aid-cncr2820440405>3.0.co;2-z.
In tumor-free and tumor-bearing mice the body clearance and organ distribution of 57Co-BLM was measured in different time intervals after iv, sc, and it administration of the drug. No significant differences could be demonstrated in body clearances following different doses and routes of application of labeled BLM in tumor-free and tumor-bearing mice. The organ distribution studies showed higher concentrations following iv compared to sc or it application of 57Co-BLM; however, the activity in the ipsilateral injection sites were significantly increased after sc and it injection. In tumor-bearing mice the activity in the draining lymph nodes of the injection site were as high as that seen in draining lymph nodes following iv injection. However, on the contralateral side, the lymph node concentration was significantly reduced after it injection. These results indicate on the basis of organ distribution of 57Co-BLM a rational basis for it treatment of malignant tumors.
在无瘤和荷瘤小鼠中,在静脉注射、皮下注射和瘤内注射药物后的不同时间间隔测量了57Co-BLM的体内清除率和器官分布。在无瘤和荷瘤小鼠中,不同剂量和给药途径应用标记的博来霉素后,体内清除率无显著差异。器官分布研究表明,与皮下或瘤内注射57Co-BLM相比,静脉注射后浓度更高;然而,皮下和瘤内注射后同侧注射部位的活性显著增加。在荷瘤小鼠中,注射部位引流淋巴结中的活性与静脉注射后引流淋巴结中的活性一样高。然而,在对侧,瘤内注射后淋巴结浓度显著降低。基于57Co-BLM的器官分布,这些结果为瘤内治疗恶性肿瘤提供了合理依据。